Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SALIM VIRANI and LAURA PETERSEN.
SALIM VIRANI
Connection Strength
16.780
LAURA PETERSEN
  1. Guideline-Concordant Statin Therapy Use?in Secondary Prevention: Should the Medical Community Wait for Divine Intervention? J Am Coll Cardiol. 2022 05 10; 79(18):1814-1817.
    View in: PubMed
    Score: 0.834
  2. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. J Clin Lipidol. 2019 Sep - Oct; 13(5):797-803.e1.
    View in: PubMed
    Score: 0.689
  3. Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
    View in: PubMed
    Score: 0.607
  4. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. Am Heart J. 2016 Nov; 181:74-82.
    View in: PubMed
    Score: 0.562
  5. Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. J Am Coll Cardiol. 2015 Oct 20; 66(16):1803-1812.
    View in: PubMed
    Score: 0.529
  6. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014 Nov; 37(11):653-9.
    View in: PubMed
    Score: 0.494
  7. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015 Jan 01; 115(1):21-6.
    View in: PubMed
    Score: 0.493
  8. Decrease the incentives to order lipid panels--reply. JAMA Intern Med. 2014 Mar; 174(3):473-4.
    View in: PubMed
    Score: 0.473
  9. Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med. 2013 Aug 12; 173(15):1439-44.
    View in: PubMed
    Score: 0.455
  10. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.416
  11. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011 Oct; 162(4):725-732.e1.
    View in: PubMed
    Score: 0.397
  12. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011 Jun; 161(6):1140-6.
    View in: PubMed
    Score: 0.389
  13. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.224
  14. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2023 05 02; 147(18):1411-1413.
    View in: PubMed
    Score: 0.221
  15. State-Level Social Vulnerability Index and Healthcare Access: The Behavioral Risk Factor Surveillance System Survey. Am J Prev Med. 2022 09; 63(3):403-409.
    View in: PubMed
    Score: 0.208
  16. A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 06; 24(6):689-698.
    View in: PubMed
    Score: 0.207
  17. Evaluation of Factors Underlying Sex-Based Disparities in Cardiovascular Care in Adults With Self-reported Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2022 Mar 01; 7(3):341-345.
    View in: PubMed
    Score: 0.206
  18. Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. Am Heart J. 2022 06; 248:160-162.
    View in: PubMed
    Score: 0.203
  19. Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease. Am J Prev Cardiol. 2022 Mar; 9:100300.
    View in: PubMed
    Score: 0.202
  20. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.200
  21. Social vulnerability and COVID-19: An analysis of CDC data. Prog Cardiovasc Dis. 2022 Jul-Aug; 73:91-93.
    View in: PubMed
    Score: 0.200
  22. Gender disparities in difficulty accessing healthcare and cost-related medication non-adherence: The CDC behavioral risk factor surveillance system (BRFSS) survey. Prev Med. 2021 12; 153:106779.
    View in: PubMed
    Score: 0.199
  23. Letter to the Editor: Temporal Changes in Cost-Related Medication Nonadherence by Race/Ethnicity and Medicaid Expansion: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):141-142.
    View in: PubMed
    Score: 0.198
  24. Prevalence and predictors of cost-related medication nonadherence in individuals with cardiovascular disease: Results from the Behavioral Risk Factor Surveillance System (BRFSS) survey. Prev Med. 2021 12; 153:106715.
    View in: PubMed
    Score: 0.197
  25. Prevalence and Determinants of Difficulty in Accessing Medical Care in U.S. Adults. Am J Prev Med. 2021 10; 61(4):492-500.
    View in: PubMed
    Score: 0.197
  26. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
    View in: PubMed
    Score: 0.196
  27. Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
    View in: PubMed
    Score: 0.196
  28. Health care costs associated with primary care physicians versus nurse practitioners and physician assistants. J Am Assoc Nurse Pract. 2021 05 31; 33(11):967-974.
    View in: PubMed
    Score: 0.195
  29. Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. Am J Med. 2021 08; 134(8):1047-1051.e2.
    View in: PubMed
    Score: 0.193
  30. Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart. 2021 04; 107(8):650-656.
    View in: PubMed
    Score: 0.191
  31. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System. Cardiovasc Drugs Ther. 2022 04; 36(2):295-300.
    View in: PubMed
    Score: 0.191
  32. Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19. Am J Prev Cardiol. 2021 Mar; 5:100150.
    View in: PubMed
    Score: 0.191
  33. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
    View in: PubMed
    Score: 0.190
  34. Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc. 2020 11 17; 9(22):e017915.
    View in: PubMed
    Score: 0.188
  35. Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19. Diabetes Care. 2021 01; 44(1):e15-e17.
    View in: PubMed
    Score: 0.188
  36. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
    View in: PubMed
    Score: 0.186
  37. Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovasc Drugs Ther. 2020 12; 34(6):745-754.
    View in: PubMed
    Score: 0.185
  38. Association of Internet Use With the Use of Addictive Substances in the United States. Am J Cardiol. 2020 11 15; 135:182-183.
    View in: PubMed
    Score: 0.185
  39. Racial and Geographic Disparities in Internet Use in the United States Among Patients with Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2020 11 01; 134:146-147.
    View in: PubMed
    Score: 0.185
  40. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
    View in: PubMed
    Score: 0.184
  41. Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. Am J Med. 2020 12; 133(12):1424-1432.e1.
    View in: PubMed
    Score: 0.183
  42. Facility-Level Variation in Cardiac Stress Test Use Among Patients With Diabetes: Findings From the Veterans Affairs National Database. Diabetes Care. 2020 05; 43(5):e58-e60.
    View in: PubMed
    Score: 0.179
  43. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.177
  44. Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system. Am Heart J. 2020 03; 221:9-18.
    View in: PubMed
    Score: 0.176
  45. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.172
  46. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019 09; 132(9):e693-e700.
    View in: PubMed
    Score: 0.170
  47. Facility-Level Variation in Stress Test Utilization in Veterans With Ischemic Heart Disease. JACC Cardiovasc Imaging. 2019 07; 12(7 Pt 1):1292-1293.
    View in: PubMed
    Score: 0.169
  48. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.167
  49. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.166
  50. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.165
  51. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
    View in: PubMed
    Score: 0.164
  52. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.160
  53. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
    View in: PubMed
    Score: 0.158
  54. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
    View in: PubMed
    Score: 0.157
  55. Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database. Clin Cardiol. 2017 Nov; 40(11):1055-1060.
    View in: PubMed
    Score: 0.150
  56. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
    View in: PubMed
    Score: 0.147
  57. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 04 01; 2(4):361-369.
    View in: PubMed
    Score: 0.146
  58. Practice-Level Variation in?Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. J Am Coll Cardiol. 2016 09 20; 68(12):1368-9.
    View in: PubMed
    Score: 0.141
  59. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
    View in: PubMed
    Score: 0.140
  60. Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clin Cardiol. 2016 Apr; 39(4):185-91.
    View in: PubMed
    Score: 0.137
  61. A dataset to assess providers? knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Data Brief. 2016 Jun; 7:595-8.
    View in: PubMed
    Score: 0.136
  62. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis. 2016 Mar; 246:115-20.
    View in: PubMed
    Score: 0.134
  63. Provider understanding of the 2013 ACC/AHA cholesterol guideline. J Clin Lipidol. 2016 May-Jun; 10(3):497-504.e4.
    View in: PubMed
    Score: 0.133
  64. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.129
  65. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
    View in: PubMed
    Score: 0.126
  66. Reply: Frequency of inappropriate and nonrecommended prasugrel prescription: great variations. J Am Coll Cardiol. 2014 Dec 09; 64(22):2434-5.
    View in: PubMed
    Score: 0.124
  67. Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014 Jul 01; 63(25 Pt A):2876-7.
    View in: PubMed
    Score: 0.120
  68. Impact of clinical complexity on the quality of diabetes care. Am J Manag Care. 2012 09; 18(9):508-14.
    View in: PubMed
    Score: 0.107
  69. Treating chronically ill people with diabetes mellitus with limited life expectancy: implications for performance measurement. J Am Geriatr Soc. 2012 Feb; 60(2):193-201.
    View in: PubMed
    Score: 0.102
  70. Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. J Clin Lipidol. 2012 Jan-Feb; 6(1):50-7.
    View in: PubMed
    Score: 0.101
  71. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
    View in: PubMed
    Score: 0.099
  72. Preoperative statin therapy decreases risk of postoperative renal insufficiency. Cardiovasc Ther. 2010 Apr; 28(2):80-6.
    View in: PubMed
    Score: 0.090
  73. Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD. J Am Soc Nephrol. 2024 Aug 26.
    View in: PubMed
    Score: 0.061
  74. State-Level Social Vulnerability Index and Healthcare Access in Patients With Atherosclerotic Cardiovascular Disease (from the BRFSS Survey). Am J Cardiol. 2022 09 01; 178:149-153.
    View in: PubMed
    Score: 0.053
  75. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.051
  76. Incorporating Guideline Adherence and Practice Implementation Issues into the Design of Decision Support for Beta-Blocker Titration for Heart Failure. Appl Clin Inform. 2018 04; 9(2):478-489.
    View in: PubMed
    Score: 0.040
  77. Impact of Patient-Centered Medical Home Implementation on Diabetes Control in the Veterans Health Administration. J Gen Intern Med. 2018 08; 33(8):1276-1282.
    View in: PubMed
    Score: 0.039
  78. Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry. J Am Heart Assoc. 2016 10 06; 5(10).
    View in: PubMed
    Score: 0.035
  79. Calculations of Financial Incentives for Providers in a Pay-for-Performance Program: Manual Review Versus Data From Structured Fields in Electronic Health Records. Med Care. 2015 Oct; 53(10):901-7.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.